Letter: Cardiovascular Events in Chronic Kidney Diseases: Related Factors Besides Naples Prognostic Score

Abstract

Get full access to this article

View all access options for this article.

References

Zhang

Liu

Chen

. Predictive value of the naples prognostic score for cardiovascular outcomes in patients with chronic kidney disease receiving percutaneous coronary intervention. Angiology. Epub 2024 Sept 19. doi:10.1177/00033197241285970

Zhang

Deng

Chen

Zeng

SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis. Front Cardiovasc Med. 2023;10:1280547.

Madero

Chertow

Mark

PB.

SGLT2 Inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health. Kidney Med. 2024;6:100851.

Hung

Lin

Tarng

DC.

Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years?

J Formos Med Assoc. 2014;113(1):3-10.

Horváth-Puhó

Suttorp

Frederiksen

, et al Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma. Clin Epidemiol. 2018;10:1371-80.

Wish

JB.

Untangling the association between anemia treatment and stroke risk in CKD. Kidney360. 2021;2:1693-5.

Agrawal

Zaritsky

Fornoni

Smoyer

WE.

Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14(1):57-70.